Express News | Tang Capital Partners LP Reports 8.2% Passive Stake in Marinus Pharmaceuticals Inc as of April 16 - SEC Filing
Moomoo 24/7Apr 19 06:12 ET
Marinus Pharmaceuticals Is Maintained at Buy by Truist Securities
Marinus Pharmaceuticals Is Maintained at Buy by Truist Securities
Dow JonesApr 18 07:24 ET
Express News | Marinus Pharmaceuticals Inc : Truist Securities Cuts Target Price to $10 From $25: Truist Securities Cuts Target Price to $10 From $25
Moomoo 24/7Apr 18 06:55 ET
Express News | Marinus Pharmaceuticals Inc : Truist Securities Cuts Target Price to $10 From $25
Moomoo 24/7Apr 17 10:59 ET
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwri
BenzingaApr 17 08:21 ET
Marinus Pharmaceuticals Price Target Cut to $2.00/Share From $20.00 by Baird
Marinus Pharmaceuticals Price Target Cut to $2.00/Share From $20.00 by Baird
Dow JonesApr 17 05:24 ET
Analysts Question Commercial Viability of Marinus' IV Ganaxolone After Interim Analysis Miss
Monday, in an interim analysis of Marinus Pharmaceuticals Inc's (NASDAQ:MRNS) phase 3 RAISE trial, evaluating intravenous (IV) ganaxolone as a treatment for refractory status epilepticus (RSE), failed
BenzingaApr 16 14:45 ET
Express News | HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target
Moomoo 24/7Apr 16 10:59 ET
Palisade Bio, Marinus Pharmaceuticals, Poseida Therapeutics Among Healthcare Movers
Seeking AlphaApr 16 10:00 ET
Express News | Marinus Pharmaceuticals Inc : RBC Cuts Target Price to $3 From $24
Moomoo 24/7Apr 16 02:11 ET
Express News | Marinus Pharmaceuticals Inc : RBC Cuts to Sector Perform From Outperform
Moomoo 24/7Apr 16 02:10 ET
Express News | Marinus Pharmaceuticals Inc : Baird Cuts to Neutral Rating; Cuts Target Price to $2 From $20
Moomoo 24/7Apr 16 01:19 ET
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks eased late Monday afternoon, with the NYSE Health Care Index decreasing 0.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.2%. The iShares Biotechnology ETF (IBB) fell 1.
MT NewswiresApr 15 15:59 ET
Marinus Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital
Marinus Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital
Dow JonesApr 15 15:02 ET
Express News | RBC Capital Downgrades Marinus Pharma to Sector Perform, Lowers Price Target to $3
Moomoo 24/7Apr 15 14:52 ET
Marinus Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/15/2024 123.96% RBC Capital $24 → $3 Downgrades Outperform → Sector Perform 04/10/2024 1990.33% Cantor
BenzingaApr 15 14:51 ET
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell sharply during Monday's session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic d
BenzingaApr 15 14:11 ET
Trending Stocks Today: Kaival Brands Innovations Shoots up 130%
April 15th - US stocks trending in regular trading hours.Gainers: $Kaival Brands Innovations(KAVL.US)$ shoots up 130% to $6.14 with a turnover of $288.45 million. $Longeveron(LGVN.US)$ surges 51.47% t
moomoo NewsApr 15 14:10 ET
Maintaining Buy Rating on Marinus Pharmaceuticals: Confidence in Research and Strategic Financial Health
TipRanksApr 15 13:25 ET
Marinus Pharmaceuticals: A Strong Buy Despite RAISE Trial Setback, With Promising Growth Potential in DEE Market
TipRanksApr 15 13:05 ET
No Data
No Data